WeTrials
Active, not recruiting

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD1390 (NSC# 852149) When Combined With Focal Radiation in Pediatric Patients With High Grade Glioma

What is this study?

This study is testing an experimental medication called AZD1390 alongside radiation therapy for children and young adults with aggressive brain tumors. The goal is to see if this combination is safe and can help radiation work better by stopping cancer cells from repairing themselves.

Who can participate?

This study is open to children and young adults between 12 months and 21 years old who have been newly diagnosed with specific types of aggressive brain or spinal cord tumors. Participants must be able to receive radiation therapy and generally cannot be taking other cancer medications.

What will happen?

Participants will receive the experimental drug combined with radiation therapy, along with routine monitoring like blood tests, MRI scans, and answering health questionnaires. Doctors will closely watch for side effects to find the best dose.

Where and when?

The study has locations in cities such as Birmingham, Phoenix, and Los Angeles, but it is currently active and not recruiting new patients at this time.

Key Points
  • 1Tests the new drug AZD1390 combined with radiation for young brain tumor patients.
  • 2Aims to make radiation therapy more effective by blocking cancer cell repair.
  • 3The study is currently active but not looking for new participants.

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline GliomaChildhood GlioblastomaChildhood Malignant Glioma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.